knowledge -WSS

knowledge

author：hotspot 2025-09-27 19:37:55 - browse：7761

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Readout Newsletter: Bluebird, CVS, Contineum

entertainment

focus

WSS

Gene editing the human germline: What are the risks?

Churchill Downs extends trainer Bob Baffert's ban through 2024

PlayStation controller and acoustic messaging: How the missing Titanic tourist sub works

Health AI adoption puts security, privacy startups on investors' radar

NASA releases new images of 'fingerprint

Leading voice in opioid treatment defends methadone clinic system

hotspot

knowledge

focus

In Memoriam: Notable people who died in 2023

Russians and Belarusians back at Wimbledon as war in Ukraine continues

As demand for Covid shots wanes, Moderna seeks its next success

4 dead, 2 in stable condition in Philadelphia shooting: Police

The cancer drug shortage isn’t new — and neither are the solutions

Churchill Downs extends trainer Bob Baffert's ban through 2024

Continuity nursing helped my family in our darkest PICU moments

Churchill Downs extends trainer Bob Baffert's ban through 2024

How to save PrEP access — and even expand it

Health AI adoption puts security, privacy startups on investors' radar

focus

Colonoscopy prep: Liquid

4 dead, 2 in stable condition in Philadelphia shooting: Police

Churchill Downs extends trainer Bob Baffert's ban through 2024

Leading voice in opioid treatment defends methadone clinic system

4 dead, 2 in stable condition in Philadelphia shooting: Police

Colonoscopy prep: Liquid

focus

entertainment

focus

entertainment